Published October 28, 2021
Thomas Russo, chief of the division of infectious disease at the Jacobs School of Medicine and Biomedical Sciences at UB, was interviewed by Prevention magazine about how the antidepressant fluvoxamine may cut the chance of hospitalization of COVID-19. It’s somewhat of a mystery on why fluvoxamine might work against COVID-19. “It’s not clear what the mechanism of action is,” said Russo. He points out that fluvoxamine isn’t an antiviral medication, and that “early on, antivirals make a little more sense for treatment of a virus like COVID-19 because they tamp down on replication.” The article also appeared onMSN.